RE:RE:RE:RE:RE:RE:AstraZeneca's ADC disappoints - on severe adverse eventsMarch 06, 2024 - " In patients with HR+/HER2- (negative) breast cancer – comprising approximately 60% to 70% of all breast cancers – an oncolytic virus called pelareorep has the potential to work in synergy with chemotherapy, hormonal therapies and immune checkpoint inhibitors (ICIs) to improve treatment outcomes where current therapies fall short."
https://www.benzinga.com/partner/biotech/24/03/37507096/oncolytics-biotech-nasdaq-oncy-tsx-onc-fights-cancer-with-pelareorep-which-has-received-fda-fast-